QIAGEN exceeded its financial targets for Q3 2025 with net sales up 6% to $533 million, sustaining growth momentum through strategic investments and operational efficiency.

• Core sales grew 6% at constant exchange rates, outpacing the 4% target, with significant contributions from QIAstat diagnostics and QuantiFERON.
• Adjusted EPS reached $0.61, surpassing guidance of at least $0.58, reflecting strong profitability despite external pressures.
• The acquisition of Parse Biosciences enhances QIAGEN's position in the fast-evolving AI-driven single-cell market, while ongoing share repurchase plans aim for over $1 billion in shareholder returns by 2028.
• The company reaffirmed its sales growth outlook of 4% to 5% at constant exchange rates for 2025, while raising adjusted EPS guidance to approximately $2.38, an increase of $0.10.